Navigation Links
Amgen Announces Webcast of 2012 First Quarter Financial Results
Date:4/19/2012

THOUSAND OAKS, Calif., April 19, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will report its first quarter financial results on Tuesday, April 24, 2012, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. Pacific Time.  Participating in the call from Amgen will be Kevin Sharer, chairman and CEO, and other members of Amgen's senior management team.

Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public.

The webcast of the conference, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 30 days after the event.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com.  Follow us on www.twitter.com/amgen.

CONTACT: Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

 


'/>"/>
SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis
2. Amgen Completes Tender Offer for Outstanding Shares of Micromet, Inc.
3. Schwartz Center Receives $500,000 Grant from the Amgen Foundation
4. Amgen to Present at the Cowen and Company 32nd Annual Healthcare Conference
5. Amgen and Micromet Announce Early Termination of HSR Waiting Period for Amgens Acquisition of Micromet
6. Amgens Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33
7. Amgen Announces Final Results of Its Tender Offer
8. Amgen Announces Preliminary Results of Its Tender Offer
9. AMG 277 Discriminates Against S1P3 Receptor by 50-fold. S1P1 Lead Compounds Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale. Assets Generated by Epix Pharmaceuticals, Inc. and Amgen.
10. Amgen Statement on European Investor Visit
11. S1P1 Lead Compounds, Assets Generated by Epix Pharmaceuticals, Inc. and Amgen, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale. Target Rationale for S1P1 Agonists Explained.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets ... the U.S.: Consumer Strategies" report to their offering. ... Pain ... approach and treat their physical pain, emphasizing consumer survey analysis, ... pain sufferers and adults who have selected illnesses/conditions strongly associated ...
(Date:3/24/2017)... March 24, 2017 ShangPharma, a ... and cost-effective drug development and discovery services, ... biotechnology industry, announced today the intent for ... will be consolidating the Contract Research Organizations ... Shanghai ChemPartner. These entities include ChemPartner Shanghai, ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... offering. ... is very strong with a total of 97 drug candidates. Pharma giant ... are involved in the development of the IPF therapeutics. The IPF pipeline ... stage, 15 are in Phase II stage, 12 are in Phase I ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health ... to prep patients for colonoscopy at the HyGIeaCare® Center that is to be ... FL. , The HyGIeaCare® Prep, cleared by the U.S. Food and ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... first Certified Medical Reiki™ Master in Frederick, MD. Judy says, “I am passionate ... during what is often a very difficult and challenging time.” , A Certified ...
(Date:3/24/2017)... ... ... Time GPS”: a dauntless and enlightened study of the second-coming of Christ, and ... published author, Wesley Gerboth, a World War II veteran, with a highly-regarded reputation as ... ninety-one, he shares the Wisdom God bestowed upon him in this publication. , ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... of inspiring stories about real people of God in congregations across the United ... Miller, a Presbyterian minister ordained in 1964 who has served congregations in seven ...
(Date:3/23/2017)... Greensboro, NC & Seattle, WA (PRWEB) , ... March 23, 2017 ... ... international public health emergency and now estimates that there could be four million Zika-related ... fastest growing epidemics to date with numbers of US cases reported per year skyrocketing ...
Breaking Medicine News(10 mins):